Viral Kansara
Seminars
Wednesday 20th January 2027
Panel Discussion: Improving Long-Acting Therapy Success Rates Through Real-World Lessons in Durability, Translation & Development
12:30 pm
- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success
Thursday 21st January 2027
Chair’s Opening Remarks
8:20 am
Thursday 21st January 2027
Looking Ahead to The Future of Ophthalmic Drug Delivery
3:30 pm
- The Next Generation of Long-Acting Ocular Delivery: Next-generation targeted and minimally invasive delivery systems beyond Intravitreal Injections to extend ocular exposure and reduce treatment burden
- Precision and Repeatable Office-Based Therapy: Advancing non-viral vectors, ASOs, siRNA, and other platforms for precise, durable, and potentially repeatable ocular therapies
- Engineering Exposure, Not Just Dose: Integrating tissue targeting, PK/PD, biomarkers, and digital twins to optimize ocular exposure, therapeutic windows, and patient selection
- AI-Powered Drug Delivery: Leveraging AI to design delivery systems, predict tissue exposure, optimize formulations, and enable more personalized ocular therapies
Thursday 21st January 2027
Chair’s Closing Remarks
4:00 pm
